StockData
Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp. (MDNAF) stock

MDNAFOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2023, năm kết thúc ngày Mar 31, 2023Last filing: 20-F on Jun 27, 2023
$0.28−0.02 (-7.63%)

Close on Oct 19, 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Mar 31, 2023

Valuation

Market cap
–
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Trading

Previous close
$0.30
Open
$0.33
Day's range
$0.27 – $0.33
Volume
42,078
Average volume (20 days)
67,985

Valuation needs the share price. It fills in once daily prices are connected and converted from CAD.

Market cap history

Month-end market cap since 2019, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodMDNAFS&P 500DifferenceMDNAF per yearS&P 500 per year
1 month-8.5%+0.6%−9.1 pts
3 months+10.8%+3.4%+7.4 pts
Year to date-58.7%+13.3%−72.0 pts
1 year-56.7%+16.6%−73.3 pts
3 years-8.5%+86.4%−94.9 pts-2.9%+23.1%
5 years-88.4%+81.9%−170.2 pts-35.0%+12.7%

Five years at a glance

Fiscal years 2019 to 2023, CAD

EPS, diluted

–
Reported period

Press releases

Releases Medicenna Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Medicenna Therapeutics

Pharmaceutical Preparations

Medicenna Therapeutics Corp. is a biotechnology company that develops engineered cytokine therapies for the treatment of cancer. The company focuses on designing selective interleukin-based molecules, including interleukin-2, interleukin-4, and interleukin-13 variants, either independently or combined with cell-killing proteins and antibodies. Its primary product candidates include MDNA11 for advanced solid tumors, bizaxofusp for recurrent glioblastoma, and bi-functional therapies termed BiSKITs. These investigational treatments are designed for cancer patients with advanced solid tumors and high-grade brain cancers.

Company profile, executives and history

Medicenna Therapeutics stock: common questions

What is Medicenna Therapeutics's stock price?

MDNAF closed at $0.28 on Oct 19, 2026, down 7.63% on the day.

Does Medicenna Therapeutics pay a dividend?

No. Medicenna Therapeutics has not paid a cash dividend over the last twelve months.

How has MDNAF stock performed over the past year?

Including dividends, MDNAF returned -56.7% over the past year, against +16.6% for the S&P 500.

Who are Medicenna Therapeutics's competitors?

Companies most similar to Medicenna Therapeutics by business, industry and size include BCTX, MBRX, KZIA, ERNA, LYEL.

See a number that looks wrong?